Kailera falls after late-stage trial data for oral GLP-1 candidate
Seeking Alpha ·
Shares of Kailera Therapeutics ( KLRA ) slipped more than 10% on Tuesday after the Waltham, Massachusetts-based biotech reported topline data from two late-stage trials conducted in China for its oral GLP-1 candidate HRS-7535 (KAI-7535). The Phase 3 HARBOR-1 trial and OUTSTAND-2
DYAX Investor Sentiment
Bullish (Long) 65% · Bearish (Short) 35%
455 participants
Related News
- Anthropic AI agent Claude Cowork now available on web, mobile
- Anthropic Is Closing the Doors To Chinese Engineers
- Ondo Unveils Perps DEX With Tokenized Stocks as Collateral
- Warren Buffett Has Recommended 1 Investment for Decades -- but There's a Hidden Risk Many Investors Are Overlooking
- Apple App Store growth slows in June quarter, UBS analysis shows
- Meta Faces $1.4 trillion Youth Safety Fight